Chemomab Therapeutics Ltd. (CMMB) stock: key figures, P/E, revenue and dividend
Health Care · ISIN US16385C2035
Chemomab Therapeutics Ltd. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -112.00 m USD |
| Net income | -9.00 m USD |
| Diluted EPS – continuing operations | 0.02 USD |
Full history since 2008, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
More stocks
- Chung Hung Steel Corp (2014.TW)
- Sun Create Electronics Co., Ltd (600990.SS)
- ACNB CORP (ACNB)
- Zhejiang Cayi Vacuum Container Co. Ltd. (301004.SZ)
- Haoxiangni Jujube Co Ltd (002582.SZ)
- Shandong Sanyuan Biotechnology Co.Ltd. (301206.SZ)
- Lightwave Logic, Inc. (LWLG)
- Ton Yi Industrial Corp (9907.TW)
- Jiangsu Huachang Chemical Co Ltd (002274.SZ)
- Ls Invest (IFA.HM)
- ArriVent BioPharma, Inc. (AVBP)
- Taboola.com Ltd. (TBLA)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.